Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL)
Conditions
Keywords
Malignant lymphatic disease, therapy-reality, observation, registry, therapy sequences, NHL, CLL, Germany, lenalidomide, alemtuzumab, rituximab, bendamustin, thalidomide, bortezomib, ibritumomab-tiuxetan, G-CSF (Granulocyte-Colony Stimulating Factor), chronic lymphocytic leukaemia, follicular lymphoma, gastric MALT lymphoma (Mucosa Associated Lymphoid Tissue), nongastric MALT lymphoma (Mucosa Associated Lymphoid Tissue), nodal marginal zone lymphoma, splenic marginal zone lymphoma, mantle cell lymphoma, diffuse large b-cell lymphoma
Brief summary
The purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in Germany.
Detailed description
The TLN is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of lymphatic neoplasms in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. The impact of nutrition (LyNut) and physical activity (LyNut) on the course of the adjuvant disease will be examined in patients with indolent and aggressive Non-Hodgin Lymphoma, as well as long-term effects of systemic treatment (LyTox) and quality of life (LyLife) in patients with multiple myeloma.
Interventions
None listed
Sponsors
iOMEDICO AG
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Confirmed diagnosis of Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia or multiple myeloma * Must receive a first- or second-line therapy * 18 years or older * Signed, written informed consent
Exclusion criteria
\- no systemic therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Course of treatment (treatment reality) | 5 years per patient | Documentation of anamnestic data and therapy sequences |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effectiveness of treatment | 5 years per patient | Documentation of response rates and progression-free survival per therapy sequence, overall survival time and adverse reactions |
Outcome results
None listed